Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy and safety in patients with chronic kidney disease (CKD) remain uncertain, as th
Background: Immune checkpoint inhibitors (ICI) have transformed outcomes for patients with advanced melanoma but are associated with acute kidney injury (AKI), including immune-rel
Single case report with no control group, describing tolerance of anti-PD-1 therapy in an unusual patient population; raises a question about feasibility rather than establishing efficacy or safety.